{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:41:31Z","timestamp":1792788091818,"version":"4.5.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"vor","delay-in-days":86,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Medicine and Pharmacy at Ho Chi Minh City","id":[{"id":"https:\/\/ror.org\/025kb2624","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diagn Pathol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>PRAME immunohistochemistry is a useful adjunct in distinguishing melanoma from benign melanocytic lesions, but its clinicopathologic associations remain incompletely understood, particularly in underrepresented populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study included 90 primary melanomas and 90 melanocytic nevi from a Vietnamese cohort. PRAME expression (clone EPR20330) was assessed using a semi-quantitative scoring system: 0 (0%), 1+ (1\u201325%), 2+ (26\u201350%), 3+ (51\u201375%), and 4+ (&gt;\u200975% of tumor cells with nuclear positivity), with 4\u2009+\u2009defined as high expression. Diagnostic performance was evaluated using receiver operating characteristic (ROC) analysis, and associations with clinicopathologic variables were analyzed using logistic regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The mean age of melanoma patients was 56.4\u2009\u00b1\u200915.9 years, with a median tumor size of 30\u00a0mm. Nodular melanoma was the most common subtype (60%), and mucosal melanoma accounted for 15.6%. Adverse features were common, including Breslow thickness\u2009&gt;\u20091\u00a0mm (87.8%), mitotic rate\u2009&gt;\u20091\/mm\u00b2 (85.6%), and ulceration (36%). High PRAME expression was observed in 73.3% of melanomas, whereas 97.8% of nevi were negative and none showed PRAME\u2009\u2265\u20092+. PRAME demonstrated excellent diagnostic performance (AUC 0.936), with sensitivity, specificity, and accuracy of 87.8%, 97.8%, and 92.8% at a cutoff of \u2265\u20091+. Tumor size\u2009&gt;\u200912\u00a0mm was independently associated with high PRAME expression in the overall cohort but not in cutaneous melanoma. No statistically significant associations were observed between PRAME expression and tumor stage in cutaneous melanoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this predominantly advanced-stage Vietnamese cohort, PRAME immunohistochemistry showed high sensitivity and specificity in distinguishing melanoma from nevi; its performance in early or thin melanomas and its broader clinicopathologic significance remain to be clarified in future studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13000-026-01806-7","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T05:45:22Z","timestamp":1784094322000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["PRAME immunohistochemistry demonstrates high diagnostic accuracy for distinguishing melanoma from nevi but no observed association with pT stage in cutaneous melanoma: a Vietnamese clinicopathological study"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9480-4602","authenticated-orcid":false,"given":"Giang Huong","family":"Tran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4464-4393","authenticated-orcid":false,"given":"Duyen Hoang-My","family":"Truong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8345-245X","authenticated-orcid":false,"given":"Lam Ngoc","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0668-8339","authenticated-orcid":false,"given":"Tu Anh","family":"Thai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3646-781X","authenticated-orcid":false,"given":"Khoa Anh","family":"Luong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"1806_CR1","doi-asserted-by":"publisher","unstructured":"Bose M. Preferentially expressed antigen in melanoma is a multifaceted cancer testis antigen with diverse roles as a biomarker and therapeutic target. Int Journal Transl Med. 2023;3(3):334\u201359. https:\/\/doi.org\/10.3390\/ijtm3030024.","DOI":"10.3390\/ijtm3030024"},{"issue":"2","key":"1806_CR2","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/s1074-7613(00)80426-4","volume":"6","author":"H Ikeda","year":"1997","unstructured":"Ikeda H, Leth\u00e9 B, Lehmann F, van Baren N, Baurain JF, de Smet C, et al. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity. 1997;6(2):199\u2013208. https:\/\/doi.org\/10.1016\/s1074-7613(00)80426-4.","journal-title":"Immunity"},{"issue":"5","key":"1806_CR3","doi-asserted-by":"publisher","first-page":"629","DOI":"10.2217\/bmm.12.65","volume":"6","author":"S Goodison","year":"2012","unstructured":"Goodison S, Urquidi V. The cancer testis antigen PRAME as a biomarker for solid tumor cancer management. Biomark Med. 2012;6(5):629\u201332. https:\/\/doi.org\/10.2217\/bmm.12.65.","journal-title":"Biomark Med"},{"key":"1806_CR4","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.2147\/ccid.S333376","volume":"14","author":"SE Dass","year":"2021","unstructured":"Dass SE, Huizenga T, Farshchian M, Mehregan DR. Comparison of SOX-10, HMB-45, and Melan-A in Benign Melanocytic Lesions. Clin Cosmet Investig Dermatol. 2021;14:1419\u201325. https:\/\/doi.org\/10.2147\/ccid.S333376.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"4","key":"1806_CR5","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1053\/j.semdp.2021.12.003","volume":"39","author":"A Saleem","year":"2022","unstructured":"Saleem A, Narala S, Raghavan SS. Immunohistochemistry in melanocytic lesions: Updates with a practical review for pathologists. Semin Diagn Pathol. 2022;39(4):239\u201347. https:\/\/doi.org\/10.1053\/j.semdp.2021.12.003.","journal-title":"Semin Diagn Pathol"},{"issue":"4","key":"1806_CR6","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1111\/cup.12475","volume":"42","author":"LE Clarke","year":"2015","unstructured":"Clarke LE, Warf MB, Flake DD 2nd, Hartman AR, Tahan S, Shea CR, et al. Clinical validation of a gene expression signature that differentiates benign nevi from malignant melanoma. J Cutan Pathol. 2015;42(4):244\u201352. https:\/\/doi.org\/10.1111\/cup.12475.","journal-title":"J Cutan Pathol"},{"issue":"10","key":"1806_CR7","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1016\/j.jid.2015.11.035","volume":"136","author":"H Mitsui","year":"2016","unstructured":"Mitsui H, Kiecker F, Shemer A, Cannizzaro MV, Wang CQF, Gulati N, et al. Discrimination of Dysplastic Nevi from Common Melanocytic Nevi by Cellular and Molecular Criteria. J Invest Dermatol. 2016;136(10):2030\u201340. https:\/\/doi.org\/10.1016\/j.jid.2015.11.035.","journal-title":"J Invest Dermatol"},{"issue":"5","key":"1806_CR8","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1158\/1078-0432.Ccr-15-2071","volume":"22","author":"MG Field","year":"2016","unstructured":"Field MG, Decatur CL, Kurtenbach S, Gezgin G, van der Velden PA, Jager MJ, et al. PRAME as an Independent Biomarker for Metastasis in Uveal Melanoma. Clin Cancer Res. 2016;22(5):1234\u201342. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-15-2071.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1806_CR9","doi-asserted-by":"publisher","first-page":"e000068","DOI":"10.1136\/esmoopen-2016-000068","volume":"1","author":"R Gutzmer","year":"2016","unstructured":"Gutzmer R, Rivoltini L, Levchenko E, Testori A, Utikal J, Ascierto PA, et al. Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study. ESMO Open. 2016;1(4):e000068. https:\/\/doi.org\/10.1136\/esmoopen-2016-000068.","journal-title":"ESMO Open"},{"issue":"6","key":"1806_CR10","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1001\/jamaophthalmol.2017.0729","volume":"135","author":"G Gezgin","year":"2017","unstructured":"Gezgin G, Luk SJ, Cao J, Dogrus\u00f6z M, van der Steen DM, Hagedoorn RS, et al. PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma. JAMA Ophthalmol. 2017;135(6):541\u20139. https:\/\/doi.org\/10.1001\/jamaophthalmol.2017.0729.","journal-title":"JAMA Ophthalmol"},{"key":"1806_CR11","unstructured":"Bastian BC, Lazar AJ, Scolyer RA, Barnhill RL, de la Fouchardi\u00e8re A, Elder DE, Gerami P, et al. Melanocytic neoplasms. In: WHO Classification of Tumours Editorial Board. Skin tumours [Internet; beta version ahead of print]. Lyon (France): Int Agency Res Cancer. 2023. [cited 2026 May 1]. https:\/\/tumourclassification.iarc.who.int\/chapters\/64"},{"key":"1806_CR12","doi-asserted-by":"publisher","first-page":"154044","DOI":"10.1016\/j.prp.2022.154044","volume":"237","author":"A Orsatti","year":"2022","unstructured":"Orsatti A, Sirolli M, Ambrosi F, Franceschini T, Giunchi F, Franchini E, et al. SOX2 and PRAME in the reprogramming of seminoma cells. Pathol Res Pract. 2022;237:154044. https:\/\/doi.org\/10.1016\/j.prp.2022.154044.","journal-title":"Pathol Res Pract"},{"issue":"5","key":"1806_CR13","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1093\/ajcp\/aqab200","volume":"157","author":"C Ricci","year":"2022","unstructured":"Ricci C, Franceschini T, Giunchi F, Grillini M, Ambrosi F, Massari F, et al. Immunohistochemical expression of preferentially expressed antigen in melanoma (PRAME) in the uninvolved background testis, germ cell neoplasia in situ, and germ cell tumors of the testis. Am J Clin Pathol. 2022;157(5):644\u20138. https:\/\/doi.org\/10.1093\/ajcp\/aqab200.","journal-title":"Am J Clin Pathol"},{"issue":"5","key":"1806_CR14","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1097\/pas.0000000000002032","volume":"47","author":"C Ricci","year":"2023","unstructured":"Ricci C, Altavilla MV, Corti B, Pasquini E, Presutti L, Baietti AM, et al. PRAME expression in mucosal melanoma of the head and neck region. Am J Surg Pathol. 2023;47(5):599\u2013610. https:\/\/doi.org\/10.1097\/pas.0000000000002032.","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"1806_CR15","doi-asserted-by":"publisher","first-page":"30254","DOI":"10.1038\/s41598-025-13085-1","volume":"15","author":"J Lin","year":"2025","unstructured":"Lin J, You Z, Chen X. To select the optimal immunohistochemical staining method for pigmented melanoma. Sci Rep. 2025;15(1):30254. https:\/\/doi.org\/10.1038\/s41598-025-13085-1.","journal-title":"Sci Rep"},{"issue":"13","key":"1806_CR16","doi-asserted-by":"publisher","first-page":"4561","DOI":"10.1002\/cam4.3065","volume":"9","author":"Q Ma","year":"2020","unstructured":"Ma Q, Suo H, Zhu L, Qian Y, Sun X, Xie J, et al. Prognostic significance of tumor size for primary invasive cutaneous melanoma: A population-based study, 2004\u20132016. Cancer Med. 2020;9(13):4561\u201371. https:\/\/doi.org\/10.1002\/cam4.3065.","journal-title":"Cancer Med"},{"key":"1806_CR17","doi-asserted-by":"publisher","unstructured":"Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI et al. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. 2017;67(6):472\u201392. https:\/\/doi.org\/10.3322\/caac.21409.","DOI":"10.3322\/caac.21409"},{"issue":"11","key":"1806_CR18","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1097\/pas.0000000000001134","volume":"42","author":"C Lezcano","year":"2018","unstructured":"Lezcano C, Jungbluth AA, Nehal KS, Hollmann TJ, Busam KJ. PRAME Expression in Melanocytic Tumors. Am J Surg Pathol. 2018;42(11):1456\u201365. https:\/\/doi.org\/10.1097\/pas.0000000000001134.","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"1806_CR19","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.abd.2019.07.003","volume":"95","author":"MH Giavina-Bianchi","year":"2020","unstructured":"Giavina-Bianchi MH, Festa-Neto C, Sanches JA, Teixeira MP, Waldvogel BC. Worse survival of invasive melanoma patients in men and de novo lesions. Bras Dermatol. 2020;95(2):158\u201364. https:\/\/doi.org\/10.1016\/j.abd.2019.07.003.","journal-title":"Bras Dermatol"},{"issue":"1","key":"1806_CR20","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jaad.2010.09.772","volume":"66","author":"U Leiter","year":"2012","unstructured":"Leiter U, Buettner PG, Eigentler TK, Br\u00f6cker EB, Voit C, Gollnick H, et al. Hazard rates for recurrent and secondary cutaneous melanoma: an analysis of 33,384 patients in the German Central Malignant Melanoma Registry. J Am Acad Dermatol. 2012;66(1):37\u201345. https:\/\/doi.org\/10.1016\/j.jaad.2010.09.772.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1806_CR21","doi-asserted-by":"publisher","first-page":"228","DOI":"10.5021\/ad.2021.33.3.228","volume":"33","author":"JH Lee","year":"2021","unstructured":"Lee JH, Choi YD, Hwang JH, Shin MH, Yun SJ. Frequency of Trauma, Physical Stress, and Occupation in Acral Melanoma: Analysis of 313 Acral Melanoma Patients in Korea. Ann Dermatol. 2021;33(3):228\u201336. https:\/\/doi.org\/10.5021\/ad.2021.33.3.228.","journal-title":"Ann Dermatol"},{"issue":"5","key":"1806_CR22","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1007\/s10147-025-02747-9","volume":"30","author":"Y Fujisawa","year":"2025","unstructured":"Fujisawa Y, Yoshikawa S, Takenouchi T, Mori S, Asai J, Uhara H, et al. Melanoma skin cancer statistics derived from 7442 Japanese patients: Japanese melanoma study. Int J Clin Oncol. 2025;30(5):844\u201355. https:\/\/doi.org\/10.1007\/s10147-025-02747-9.","journal-title":"Int J Clin Oncol"},{"key":"1806_CR23","doi-asserted-by":"publisher","unstructured":"Cazzato G, Cascardi E, Colagrande A, Belsito V, Lospalluti L, Foti C, et al. PRAME immunoexpression in 275 cutaneous melanocytic lesions: a double institutional experience. Diagnostics (Basel). 2022;12(9). https:\/\/doi.org\/10.3390\/diagnostics12092197.","DOI":"10.3390\/diagnostics12092197"},{"key":"1806_CR24","doi-asserted-by":"publisher","unstructured":"Carb\u00f3-Bagu\u00e9 A, Rubi\u00f3-Casadevall J, Puigdemont M, Sanvisens A, Oliveras G, Coll M, et al. Epidemiology and molecular profile of mucosal melanoma: a population-based study in Southern Europe. Cancers (Basel). 2022;14(3). https:\/\/doi.org\/10.3390\/cancers14030780.","DOI":"10.3390\/cancers14030780"},{"issue":"7","key":"1806_CR25","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1097\/pas.0000000000001492","volume":"44","author":"C Lezcano","year":"2020","unstructured":"Lezcano C, Jungbluth AA, Busam KJ. Comparison of immunohistochemistry for PRAME with cytogenetic test results in the evaluation of challenging melanocytic tumors. Am J Surg Pathol. 2020;44(7):893\u2013900. https:\/\/doi.org\/10.1097\/pas.0000000000001492.","journal-title":"Am J Surg Pathol"},{"issue":"12","key":"1806_CR26","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1111\/cup.13812","volume":"47","author":"SS Raghavan","year":"2020","unstructured":"Raghavan SS, Wang JY, Toland A, Bangs CD, Rieger KE, Novoa RA, et al. Diffuse PRAME expression is highly specific for malignant melanoma in the distinction from clear cell sarcoma. J Cutan Pathol. 2020;47(12):1226\u20138. https:\/\/doi.org\/10.1111\/cup.13812.","journal-title":"J Cutan Pathol"},{"issue":"8","key":"1806_CR27","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1097\/dad.0000000000001607","volume":"42","author":"D Tio","year":"2020","unstructured":"Tio D, Willemsen M, Krebbers G, Kasiem FR, Hoekzema R, van Doorn R, et al. Differential expression of cancer testis antigens on lentigo maligna and lentigo maligna melanoma. Am J Dermatopathol. 2020;42(8):625\u20137. https:\/\/doi.org\/10.1097\/dad.0000000000001607.","journal-title":"Am J Dermatopathol"},{"issue":"7","key":"1806_CR28","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1111\/cup.13958","volume":"48","author":"ME Lohman","year":"2021","unstructured":"Lohman ME, Steen AJ, Grekin RC, North JP. The utility of PRAME staining in identifying malignant transformation of melanocytic nevi. J Cutan Pathol. 2021;48(7):856\u201362. https:\/\/doi.org\/10.1111\/cup.13958.","journal-title":"J Cutan Pathol"},{"issue":"9","key":"1806_CR29","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1111\/cup.14000","volume":"48","author":"AK Alomari","year":"2021","unstructured":"Alomari AK, Tharp AW, Umphress B, Kowal RP. The utility of PRAME immunohistochemistry in the evaluation of challenging melanocytic tumors. J Cutan Pathol. 2021;48(9):1115\u201323. https:\/\/doi.org\/10.1111\/cup.14000.","journal-title":"J Cutan Pathol"},{"issue":"11","key":"1806_CR30","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1097\/dad.0000000000001885","volume":"43","author":"PB Googe","year":"2021","unstructured":"Googe PB, Flanigan KL, Miedema JR. Preferentially expressed antigen in melanoma immunostaining in a series of melanocytic neoplasms. Am J Dermatopathol. 2021;43(11):794\u2013800. https:\/\/doi.org\/10.1097\/dad.0000000000001885.","journal-title":"Am J Dermatopathol"},{"issue":"12","key":"1806_CR31","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1097\/dad.0000000000001951","volume":"43","author":"NT Harvey","year":"2021","unstructured":"Harvey NT, Peverall J, Acott N, Mesbah Ardakani N, Leecy TN, Iacobelli J, et al. Correlation of FISH and PRAME immunohistochemistry in ambiguous superficial cutaneous melanocytic proliferations. Am J Dermatopathol. 2021;43(12):913\u201320. https:\/\/doi.org\/10.1097\/dad.0000000000001951.","journal-title":"Am J Dermatopathol"},{"key":"1806_CR32","doi-asserted-by":"publisher","unstructured":"Gassenmaier M, Hahn M, Metzler G, Bauer J, Yazdi AS, Keim U, et al. Diffuse PRAME expression is highly specific for thin melanomas in the distinction from severely dysplastic nevi but does not distinguish metastasizing from non-metastasizing thin melanomas. Cancers (Basel). 2021;13(15). https:\/\/doi.org\/10.3390\/cancers13153864.","DOI":"10.3390\/cancers13153864"},{"key":"1806_CR33","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.humpath.2021.12.008","volume":"121","author":"A Fattori","year":"2022","unstructured":"Fattori A, de la Fouchardi\u00e8re A, Cribier B, Mitcov M. Preferentially expressed Antigen in MElanoma immunohistochemistry as an adjunct for evaluating ambiguous melanocytic proliferation. Hum Pathol. 2022;121:19\u201328. https:\/\/doi.org\/10.1016\/j.humpath.2021.12.008.","journal-title":"Hum Pathol"},{"issue":"3","key":"1806_CR34","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1111\/cup.14130","volume":"49","author":"JD McBride","year":"2022","unstructured":"McBride JD, McAfee JL, Piliang M, Bergfeld WF, Fernandez AP, Ronen S, et al. Preferentially expressed antigen in melanoma and p16 expression in acral melanocytic neoplasms. J Cutan Pathol. 2022;49(3):220\u201330. https:\/\/doi.org\/10.1111\/cup.14130.","journal-title":"J Cutan Pathol"},{"issue":"6","key":"1806_CR35","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/cup.14212","volume":"49","author":"H Olds","year":"2022","unstructured":"Olds H, Utz S, Abrams J, Terrano D, Mehregan D. Use of PRAME immunostaining to distinguish early melanoma in situ from benign pigmented conditions. J Cutan Pathol. 2022;49(6):510\u20134. https:\/\/doi.org\/10.1111\/cup.14212.","journal-title":"J Cutan Pathol"},{"issue":"9","key":"1806_CR36","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1111\/cup.14267","volume":"49","author":"MK O\u2019Connor","year":"2022","unstructured":"O\u2019Connor MK, Dai H, Fraga GR. PRAME immunohistochemistry for melanoma diagnosis: A STARD-compliant diagnostic accuracy study. J Cutan Pathol. 2022;49(9):780\u20136. https:\/\/doi.org\/10.1111\/cup.14267.","journal-title":"J Cutan Pathol"},{"issue":"10","key":"1806_CR37","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1097\/dad.0000000000002230","volume":"44","author":"G Santandrea","year":"2022","unstructured":"Santandrea G, Longo C, Borsari S, Lai M, Piana S. Pigmented Actinic Keratosis Versus In Situ Melanoma: PRAME May Be Helpful. Am J Dermatopathol. 2022;44(10):784\u20136. https:\/\/doi.org\/10.1097\/dad.0000000000002230.","journal-title":"Am J Dermatopathol"},{"issue":"2","key":"1806_CR38","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/his.14814","volume":"82","author":"YP Chen","year":"2023","unstructured":"Chen YP, Zhang WW, Qiu YT, Ke LF, Chen H, Chen G. PRAME is a useful marker for the differential diagnosis of melanocytic tumours and histological mimics. Histopathology. 2023;82(2):285\u201395. https:\/\/doi.org\/10.1111\/his.14814.","journal-title":"Histopathology"},{"issue":"8","key":"1806_CR39","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1111\/cup.14438","volume":"50","author":"HF Bahmad","year":"2023","unstructured":"Bahmad HF, Oh KS, Alexis J. Potential diagnostic utility of PRAME and p16 immunohistochemistry in melanocytic nevi and malignant melanoma. J Cutan Pathol. 2023;50(8):763\u201372. https:\/\/doi.org\/10.1111\/cup.14438.","journal-title":"J Cutan Pathol"},{"key":"1806_CR40","doi-asserted-by":"publisher","first-page":"155543","DOI":"10.1016\/j.prp.2024.155543","volume":"262","author":"J Enevoldsen","year":"2024","unstructured":"Enevoldsen J, Brog\u00e5rd MB, Lade-Keller J, Christensen KB, Georgsen JB, Nielsen PS, et al. Digital quantification of PRAME for distinguishing melanoma from nevi compared to manual assessment. Pathol Res Pract. 2024;262:155543. https:\/\/doi.org\/10.1016\/j.prp.2024.155543.","journal-title":"Pathol Res Pract"},{"issue":"1","key":"1806_CR41","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1097\/dad.0000000000002584","volume":"46","author":"N Turner","year":"2024","unstructured":"Turner N, Ko CJ, McNiff JM, Galan A. Pitfalls of PRAME Immunohistochemistry in a Large Series of Melanocytic and Nonmelanocytic Lesions With Literature Review. Am J Dermatopathol. 2024;46(1):21\u201330. https:\/\/doi.org\/10.1097\/dad.0000000000002584.","journal-title":"Am J Dermatopathol"},{"issue":"5","key":"1806_CR42","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1111\/pcmr.13053","volume":"35","author":"JS Chauhan","year":"2022","unstructured":"Chauhan JS, H\u00f6lzel M, Lambert JP, Buffa FM, Goding CR. The MITF regulatory network in melanoma. Pigment Cell Melanoma Res. 2022;35(5):517\u201333. https:\/\/doi.org\/10.1111\/pcmr.13053.","journal-title":"Pigment Cell Melanoma Res"},{"issue":"7","key":"1806_CR43","first-page":"2353","volume":"63","author":"M Gelmi","year":"2022","unstructured":"Gelmi M, Marinkovic M, Vu THK, van der Velden PA, Luyten GPM, Jager MJ. MITF: a progression marker in uveal melanoma. Investig Ophthalmol Vis Sci. 2022;63(7):2353\u2013A0022. A0022.","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"7","key":"1806_CR44","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1007\/s00417-019-04335-w","volume":"257","author":"AC Schefler","year":"2019","unstructured":"Schefler AC, Koca E, Bernicker EH, Correa ZM. Relationship between clinical features, GEP class, and PRAME expression in uveal melanoma. Graefes Arch Clin Exp Ophthalmol. 2019;257(7):1541\u20135. https:\/\/doi.org\/10.1007\/s00417-019-04335-w.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1806_CR45","doi-asserted-by":"publisher","unstructured":"Ronchi A, Cazzato G, Ingravallo G, D\u2019Abbronzo G, Argenziano G, Moscarella E, et al. PRAME is an effective tool for the diagnosis of nevus-associated cutaneous melanoma. Cancers (Basel). 2024;16(2). https:\/\/doi.org\/10.3390\/cancers16020278.","DOI":"10.3390\/cancers16020278"},{"key":"1806_CR46","doi-asserted-by":"publisher","unstructured":"Raghavan SS, Wang JY, Kwok S, Rieger KE, Novoa RA, Brown RA. PRAME expression in melanocytic proliferations with intermediate histopathologic or spitzoid features. 2020. 47(12): pp. 1123\u201331. https:\/\/doi.org\/10.1111\/cup.13818","DOI":"10.1111\/cup.13818"},{"issue":"10","key":"1806_CR47","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1111\/cup.14495","volume":"50","author":"O Parra","year":"2023","unstructured":"Parra O, Ma W, Li Z, Coffing BN, Linos K, LeBlanc RE, et al. PRAME expression in cutaneous melanoma does not correlate with disease-specific survival. J Cutan Pathol. 2023;50(10):903\u201312. https:\/\/doi.org\/10.1111\/cup.14495.","journal-title":"J Cutan Pathol"},{"issue":"1","key":"1806_CR48","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1097\/pai.0000000000000972","volume":"30","author":"M Grillini","year":"2022","unstructured":"Grillini M, Ricci C, Pino V, Pedrini S, Fiorentino M, Corti B. HMB45\/PRAME, a novel double staining for the diagnosis of melanocytic neoplasms: technical aspects, results, and comparison with other commercially available staining (PRAME and Melan A\/PRAME). Appl Immunohistochem Mol Morphol. 2022;30(1):14\u20138. https:\/\/doi.org\/10.1097\/pai.0000000000000972.","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"4","key":"1806_CR49","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1097\/pas.0000000000001393","volume":"44","author":"C Lezcano","year":"2020","unstructured":"Lezcano C, Pulitzer M, Moy AP, Hollmann TJ, Jungbluth AA, Busam KJ. Immunohistochemistry for PRAME in the distinction of nodal nevi from metastatic melanoma. Am J Surg Pathol. 2020;44(4):503\u20138. https:\/\/doi.org\/10.1097\/pas.0000000000001393.","journal-title":"Am J Surg Pathol"},{"key":"1806_CR50","doi-asserted-by":"publisher","unstructured":"Ricci C, Dika E, Ambrosi F, Lambertini M, Veronesi G, Barbara C. Cutaneous melanomas: a single center experience on the usage of immunohistochemistry applied for the diagnosis. Int J Mol Sci. 2022;23(11). https:\/\/doi.org\/10.3390\/ijms23115911.","DOI":"10.3390\/ijms23115911"}],"container-title":["Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13000-026-01806-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-026-01806-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-026-01806-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:55:45Z","timestamp":1791500145000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13000-026-01806-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1806"],"URL":"https:\/\/doi.org\/10.1186\/s13000-026-01806-7","relation":{},"ISSN":["1746-1596"],"issn-type":[{"value":"1746-1596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"assertion":[{"value":"4 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Institutional Review Board of Biomedical Research at the University of Medicine and Pharmacy at Ho Chi Minh City (IRB number 4042\/H\u0110\u0110\u0110-\u0110HYD on December 12, 2024) and performed following the principles of the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Due to the retrospective nature of this study, the requirement for informed consent to participate and for consent for publication was waived after review and approval by the Institutional Review Board of Biomedical Research at the University of Medicine and Pharmacy at Ho Chi Minh City.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"72"}}